WO2011074636A1 - 抗認知症薬物の経皮吸収製剤 - Google Patents
抗認知症薬物の経皮吸収製剤 Download PDFInfo
- Publication number
- WO2011074636A1 WO2011074636A1 PCT/JP2010/072667 JP2010072667W WO2011074636A1 WO 2011074636 A1 WO2011074636 A1 WO 2011074636A1 JP 2010072667 W JP2010072667 W JP 2010072667W WO 2011074636 A1 WO2011074636 A1 WO 2011074636A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- acid ester
- preparation according
- meth
- styrene
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 68
- 229940005524 anti-dementia drug Drugs 0.000 title claims abstract description 29
- 239000002664 nootropic agent Substances 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 72
- 229940079593 drug Drugs 0.000 claims abstract description 67
- -1 alcohol fatty acid ester Chemical class 0.000 claims abstract description 49
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 29
- 239000000194 fatty acid Substances 0.000 claims abstract description 29
- 229930195729 fatty acid Natural products 0.000 claims abstract description 29
- 125000003277 amino group Chemical group 0.000 claims abstract description 19
- 230000002205 anti-dementic effect Effects 0.000 claims abstract description 6
- 229940126585 therapeutic drug Drugs 0.000 claims abstract description 6
- 150000005846 sugar alcohols Polymers 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 31
- 229920000642 polymer Polymers 0.000 claims description 31
- 238000010521 absorption reaction Methods 0.000 claims description 28
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical group [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 27
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 24
- 229920001577 copolymer Polymers 0.000 claims description 24
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000178 monomer Chemical group 0.000 claims description 10
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims description 10
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims description 9
- 229960003135 donepezil hydrochloride Drugs 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 7
- 150000001336 alkenes Chemical class 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- CXMXRPHRNRROMY-UHFFFAOYSA-N n-Decanedioic acid Natural products OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 4
- 229920006132 styrene block copolymer Polymers 0.000 claims description 4
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 claims description 4
- 229960002024 galantamine hydrobromide Drugs 0.000 claims description 3
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 claims description 3
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 229960000967 memantine hydrochloride Drugs 0.000 claims description 3
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 3
- 229960004323 rivastigmine tartrate Drugs 0.000 claims description 3
- 229960003565 tacrine hydrochloride Drugs 0.000 claims description 3
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 claims description 3
- 230000037384 skin absorption Effects 0.000 claims 1
- 231100000274 skin absorption Toxicity 0.000 claims 1
- 238000013271 transdermal drug delivery Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 6
- 229920002521 macromolecule Polymers 0.000 abstract 2
- 239000010410 layer Substances 0.000 description 56
- 210000003491 skin Anatomy 0.000 description 33
- 239000012790 adhesive layer Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 description 6
- 239000005020 polyethylene terephthalate Substances 0.000 description 6
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 125000005907 alkyl ester group Chemical group 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000004907 flux Effects 0.000 description 5
- 239000011505 plaster Substances 0.000 description 5
- 229940035044 sorbitan monolaurate Drugs 0.000 description 5
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 229920000058 polyacrylate Polymers 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000001069 triethyl citrate Substances 0.000 description 4
- 235000013769 triethyl citrate Nutrition 0.000 description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229920005597 polymer membrane Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920002633 Kraton (polymer) Polymers 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000007767 bonding agent Substances 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- ZIUSSTSXXLLKKK-KOBPDPAPSA-N (1e,4z,6e)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-KOBPDPAPSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- SPSSULHKWOKEEL-UHFFFAOYSA-N 2,4,6-trinitrotoluene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O SPSSULHKWOKEEL-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Definitions
- the present invention relates to a transdermally absorbable preparation that enables an antidementia drug to be stably administered over a long period of time.
- transdermal administration of antidementia drugs is particularly useful for patients with advanced symptoms, as they can be administered continuously for a long period of time, avoiding difficulties in taking them. It is done.
- Japanese Patent Application Laid-Open No. 11-315016 discloses an ointment for transdermal administration of an antidementia drug and a suppository for rectal administration, and includes a group containing a higher alcohol and an ester derivative thereof.
- the material is said to improve the transdermal absorbability of donepezil hydrochloride.
- WO 03/032960 discloses a transdermal absorption dementia treatment preparation containing an adhesive composition, wherein the adhesive composition contains an active ingredient dispersed therein, and the active ingredient has a pharmacologically effective rate. And a skin permeation rate of at least 1.2 ⁇ g / cm 2 per hour is disclosed. Further, in Examples, a preparation comprising an adhesive composition comprising donepezil hydrochloride as an active ingredient, a styrene-isoprene-styrene block copolymer as a hydrophobic polymer, and sodium acetate as an organic acid salt And the size of the 24-hour single dose formulation is 60 cm 2 .
- transdermal preparation it is necessary that the drug as the active ingredient is held without being precipitated in the preparation and is stably placed on the skin.
- studies have been made on transdermally absorbable preparations and materials thereof.
- JP-A-10-182439 discloses adhesion and bonding agents for skin or transdermal therapeutic systems, which comprise (meth) acrylate copolymers containing tertiary or quaternary amino groups and An adhesion-bonding agent comprising an acid group-containing acrylate- or (meth) acrylate polymer or copolymer and a softening agent is disclosed.
- An adhesion-bonding agent comprising an acid group-containing acrylate- or (meth) acrylate polymer or copolymer and a softening agent is disclosed.
- Triethyl citrate and acetyl triethyl citrate are disclosed as softeners in the examples.
- WO02 / 38139 discloses a percutaneous absorption preparation containing a polymer compound having an amino group, a drug forming an acid addition salt, and a carboxylic acid and / or a salt thereof.
- Japanese Patent Application Laid-Open No. 4-117323 discloses a transdermal absorption patch in which an adhesive layer containing an adhesive base and a drug is held on a support, a fixed amount of drug in an acid addition form, a fixed amount
- a transdermal absorption patch comprising a polymer containing basic nitrogen and having no adhesiveness to the skin at room temperature is disclosed.
- WO2007 / 129427 discloses a percutaneous absorption preparation of an antidementia drug, which has at least an adhesive layer, an intermediate film, and a drug-containing layer in order from the side applied to the skin.
- a reservoir-type transdermally absorbable preparation is disclosed.
- the drug-containing layer of this transdermally absorbable preparation comprises at least an anti-dementia therapeutic drug, a polymer compound having an amino group, a polyhydric alcohol, and one or more carboxylic acid esters. It has been reported that even a single dose can be set for a long period of time and can be set to about one week.
- the application area of the preparation increases as the drug amount increases, the application position is limited, and it is often difficult to use a transdermal preparation depending on the patient. It becomes. Therefore, it is necessary to reduce the size of a percutaneous absorption preparation used for a long period of time of about one week. Further, when reducing the size of the transdermally absorbable preparation, in order to obtain a desired therapeutic effect, it is required to increase the amount of drug released per application area while maintaining a stable drug release ability.
- JP-A-11-3151616 WO03 / 032960 Japanese Patent Laid-Open No. 10-182439 WO02 / 38139 Publication JP-A-4-117323 WO2007 / 129427
- the object of the present invention is to provide a novel transdermally absorbable preparation capable of releasing an antidementia drug stably and efficiently over a long period of about one week.
- the transdermally absorbable preparation according to the present invention contains an anti-dementia therapeutic drug, a polymer compound having an amino group, a polyhydric alcohol fatty acid ester, a polyhydric alcohol, a polyvalent carboxylic acid ester, and a styrenic polymer compound. And a drug-containing layer.
- the transdermally absorbable preparation according to the present invention can release an antidementia drug stably and efficiently over a long period of about one week.
- A is a cross-sectional view of the transdermal absorption preparation
- B is a skin contact surface view of the transdermal absorption preparation.
- It is a graph which shows the result of a 1 week in-vitro human skin permeation test using the transdermal absorption agent by this invention.
- 1 is a graph showing changes in the plasma concentration of an antidementia drug in rabbits for one week when a transdermal absorption preparation according to the present invention is administered once.
- alkyl means linear, branched or cyclic alkyl, and preferably has 2 to 18 carbon atoms in total.
- the “alcohol” means a linear, branched or cyclic saturated or unsaturated alcohol.
- Transdermally absorbable preparation comprises a drug-containing layer having a specific composition as described above. It is a surprising fact that a percutaneously absorbable preparation having such a drug-containing layer exhibits a significantly high drug release amount per affixed area and can stably release the drug over a long period of about one week.
- the antidementia drug of the present invention is preferably a basic drug.
- the antidementia drug is a nitrogen-containing basic drug or a salt thereof, and the salt is not particularly limited as long as it is a pharmacologically acceptable salt.
- the basic drug or a salt thereof is preferably donepezil hydrochloride, memantine hydrochloride, rivastigmine tartrate, galantamine hydrobromide, or tacrine hydrochloride, and more preferably donepezil hydrochloride.
- the content of the antidementia drug in the drug-containing layer can be, for example, 0.5 to 50% by mass, preferably 10 to 40% by mass, and more preferably considering long-term administration. 15 to 35% by mass.
- a drug-containing layer that can contain a drug up to a high dose is advantageous in producing a percutaneous absorption preparation having a size suitable for actual use.
- the polymer compound having an amino group in the drug-containing layer is preferably selected from dialkylaminoalkyl (meth) acrylate, alkyl (meth) acrylate, hydroxyalkyl (meth) acrylate, and combinations thereof. It is a copolymer composed of monomer units. Such a copolymer is advantageous in stably holding the drug and achieving a good drug flux.
- the polymer compound having an amino group is preferably an acrylic (meth) acrylate, an alkyl (meth) acrylate, a dialkylaminoethyl (meth) acrylate copolymer, more preferably a (meth) acrylic acid diC1.
- a copolymer comprising ⁇ 2 alkylamino C1-2 alkyl, C1-4 alkyl (meth) acrylate, and monohydroxy C2-4 alkyl (meth) acrylate as monomer units, more preferably (meth) A methyl acrylate / butyl (meth) acrylate / dimethylaminoethyl (meth) acrylate copolymer, more preferably a methyl methacrylate / butyl acrylate / dimethylaminoethyl methacrylate copolymer.
- Such a methyl methacrylate / butyl methacrylate / dimethylaminoethyl methacrylate copolymer is commercially available, for example, as Eudragit (registered trademark) E100 (Degussa).
- the molar ratio of monomer units, molecular weight, and the like can be appropriately adjusted by those skilled in the art.
- the content of the polymer compound having an amino group in the drug-containing layer is preferably 5 to 30% by mass, more preferably 10 to 25% by mass.
- the polyvalent carboxylic acid ester is preferably a divalent to hexavalent carboxylic acid ester, a divalent to trivalent carboxylic acid C1 to 6 alkyl ester, and more preferably a divalent to trivalent carboxylic acid C1 to 6 alkyl ester. More preferably, it is a C 1-3 alkyl ester of a bivalent or trivalent carboxylic acid, more preferably a tri C 1-3 alkyl ester of citric acid or a di C 1-3 alkyl ester of sebacic acid, more preferably triethyl citrate or sebacic acid. Diethyl.
- the content of the polyvalent carboxylic acid ester in the drug-containing layer is preferably 1 to 10% by mass, and more preferably 2 to 5% by mass.
- the polyhydric alcohol is preferably a sugar alcohol or glycol, more preferably glycerin or glycol, and still more preferably at least one selected from the group consisting of tritol, pentitol, hexitol and glycol. . More specifically, the polyhydric alcohol is selected from glycerin, propylene glycol, dipropylene glycol, butylene glycol, d-sorbitol, xylitol, mannitol, polyethylene glycol and combinations thereof, more preferably glycerin. is there.
- the content of polyhydric alcohol in the drug-containing layer is preferably 1 to 10% by mass, more preferably 3 to 10% by mass.
- the polyhydric alcohol fatty acid ester is preferably a sugar alcohol fatty acid ester or a glycol fatty acid ester, more preferably at least one selected from the group consisting of sorbitan fatty acid ester, propylene glycol fatty acid ester and glycerin fatty acid ester. More preferably, it is a sorbitan fatty acid ester. More specific examples of polyhydric alcohol fatty acid esters include sorbitan monolaurate, sorbitan monostearate, sorbitan monooleate, sorbitan monopalmitate, sorbitan trioleate or sorbitan tristearate, preferably It is sorbitan monolaurate.
- the content of the polyhydric alcohol fatty acid ester in the drug-containing layer is preferably 3 to 15% by mass, more preferably 3 to 10% by mass.
- the styrenic polymer compound is not particularly limited as long as it does not hinder the release and retention of the drug, but is preferably a copolymer of styrene and a polymerizable alkene having 2 to 8 carbon atoms, more preferably.
- the molar ratio of monomer units, molecular weight, and the like are appropriately adjusted by those skilled in the art.
- the content of the styrenic polymer compound in the drug-containing layer is preferably 5 to 60% by mass, and more preferably 15 to 50% by mass.
- the drug-containing layer in the present invention can be formed by appropriately combining as long as the above-described constituent components and their amounts are used.
- the drug-containing layer comprises a basic antidementia drug or a salt thereof; dialkylaminoalkyl (meth) acrylate, alkyl (meth) acrylate, hydroxyalkyl (meth) acrylate.
- a polymer compound having an amino group which is a copolymer composed of monomer units selected from these and combinations thereof; polyhydric alcohol fatty acid ester; polyhydric alcohol; polyhydric carboxylic acid ester; and styrenic polymer Comprising a compound.
- the drug-containing layer comprises a basic antidementia drug or a salt thereof, dialkylaminoalkyl (meth) acrylate, alkyl (meth) acrylate, hydroxy (meth) acrylate.
- a polymer compound having an amino group which is a copolymer composed of a monomer unit selected from alkyl and a combination thereof; a polyhydric alcohol fatty acid ester; a polyhydric alcohol; a polycarboxylic acid ester; and styrene; It comprises a styrenic polymer compound that is a copolymer with a polymerizable alkene having 2 to 8 carbon atoms.
- the drug-containing layer comprises a basic antidementia drug or a salt thereof, dialkylaminoalkyl (meth) acrylate, alkyl (meth) acrylate, hydroxy (meth) acrylate.
- a polymer compound having an amino group which is a copolymer composed of a monomer unit selected from alkyl and a combination thereof; a polyhydric alcohol fatty acid ester; a polyhydric alcohol; a polyhydric alcohol that is a divalent to hexavalent carboxylic acid ester A carboxylic acid ester; and a styrene polymer compound that is a copolymer of styrene and a polymerizable alkene having 2 to 8 carbon atoms.
- the drug-containing layer comprises a basic antidementia drug or a salt thereof, dialkylaminoalkyl (meth) acrylate, alkyl (meth) acrylate, hydroxy (meth) acrylate.
- the drug-containing layer comprises a basic antidementia drug or a salt thereof, dialkylaminoalkyl (meth) acrylate, alkyl (meth) acrylate, hydroxy (meth) acrylate.
- a polymer compound having an amino group which is a copolymer composed of a monomer unit selected from alkyl and a combination thereof; a polyhydric alcohol fatty acid ester which is a sugar alcohol fatty acid ester or a glycol fatty acid ester; a sugar alcohol or glycol And a copolymer of styrene and a polymerizable alkene having 2 to 8 carbon atoms.
- the drug-containing layer has an amino group which is a basic antidementia drug or a salt thereof; a methyl methacrylate / butyl methacrylate / dimethylaminoethyl methacrylate copolymer.
- a polyhydric alcohol fatty acid ester that is a sugar alcohol fatty acid ester; a polyhydric alcohol that is glycerin or glycol; a polyvalent carboxylic acid ester that is a sebacic acid ester or a citrate ester; and a styrene-isoprene-styrene block copolymer.
- styrene-based polymer compound which is a styrene-butylene-styrene block copolymer or a styrene-butadiene-styrene block copolymer.
- the basic antidementia drug or a salt thereof is preferably donepezil hydrochloride, memantine hydrochloride, rivastigmine tartrate, galantamine hydrobromide, or tacrine hydrochloride, more preferably donepezil hydrochloride.
- the polymer compound having an amino group is preferably an (meth) acrylic acid acrylate / (meth) acrylate alkyl / (meth) acrylate dialkylaminoethyl copolymer, more preferably It is a methyl methacrylate / butyl methacrylate / dimethylaminoethyl methacrylate copolymer.
- the polyhydric alcohol fatty acid ester is preferably a sugar alcohol fatty acid ester, and more preferably a sorbitan fatty acid ester.
- the polyhydric alcohol is preferably glycerin or glycol, more preferably glycerin.
- the polyvalent carboxylic acid ester is preferably a di- to hexa-valent carboxylic acid ester, more preferably a di- to tri-valent carboxylic acid C1-6 alkyl ester, and even more preferably sebacin. Acid ester or citrate ester.
- the styrene polymer compound is preferably a styrene-isoprene-styrene block copolymer, a styrene-butylene-styrene block copolymer, or a styrene-butadiene-styrene block copolymer. More preferred is a styrene-isoprene-styrene block copolymer.
- the thickness of the drug-containing layer in the present invention is appropriately determined by those skilled in the art in consideration of the drug amount and the like, and can be, for example, 50 to 150 ⁇ m.
- the above-mentioned drug-containing layer can also be applied to the patient's skin as it is, and the present invention includes such an embodiment.
- the drug-containing layer of the transdermally absorbable preparation according to the present invention may be used as it is as a percutaneously absorbable preparation, but preferably comprises means for fixing the drug-containing layer.
- FIG. 1 is a cross-sectional view showing an embodiment of a transdermally absorbable preparation according to the present invention.
- the percutaneous absorption preparation comprises, in order from the skin side, a laminate composed of the drug-containing layer 4 and the support layer 3, and fixing means (1, 2) that can fix the laminate on the skin. 2).
- the fixing means (1, 2) includes a cover layer 1 that covers the laminated body and an adhesive layer 2 that adheres the cover layer 1 to the skin.
- the cover layer 1 is configured so as to cover a portion other than the skin contact surface of the laminate.
- the adhesive layer 2 is disposed on the skin side of the cover layer 1.
- FIG. 1B shows the skin contact surface of the transdermally absorbable preparation, and the adhesive layer 2 is disposed at the peripheral edge / end of the drug-containing layer 4 and adheres to the skin, thereby transdermally absorbing.
- the formulation can be fixed on the skin. Such a configuration is advantageous in maintaining the adhesion stability of the transdermally absorbable preparation to the skin.
- the drug-containing layer may be in contact with the skin as it is, or a drug-permeable polymer membrane for adjusting drug permeability is provided on a part of one side of the drug-containing layer on the skin side. Such an embodiment is also included in the present invention.
- the adhesive layer is not particularly limited as long as it is a biocompatible material capable of adhering the skin and the transdermally absorbable preparation, but is preferably polyacrylate, polydimethylsiloxane, polyisobutylene or a combination thereof. Furthermore, for example, a known tackifier may be appropriately added to the constituent material of the adhesive layer.
- the above-mentioned material can also be used as an auxiliary pressure-sensitive adhesive added to the surface of the drug-permeable membrane.
- the contact area of the adhesive layer with the skin can be appropriately determined in consideration of the area of the drug-permeable membrane, the administration period, the application site, and the like.
- the drug-permeable polymer membrane is not limited as long as it can control the release of the drug to the skin, but is preferably a microporous membrane having pores that can permeate the drug.
- the constituent material of the drug-permeable polymer membrane is not particularly reduced, but examples include EVA (ethylene-vinyl acetate copolymer), polyethylene, polypropylene, polyacrylonitrile, polymethyl methacrylate, and combinations thereof.
- the support may be stretchable or non-stretchable.
- the specific material constituting the support is not particularly limited as long as the drug-containing layer can be isolated from other members.
- woven fabric, non-woven fabric, PET (polyethylene terephthalate), polyurethane, polyester, polyethylene, or those materials A composite material etc. are mentioned.
- the cover can use the material similar to a support body, for example.
- a preferred production method of the transdermally absorbable preparation according to the present invention is as follows. First, the components of the drug-containing layer according to the present invention are appropriately mixed in a solvent to prepare a mixed solution containing the components in the solvent. Next, this mixed solution is used as a plaster solution and applied onto a liner. Next, the plaster solution is dried at about 60 to 120 ° C. to obtain a drug-containing layer. If desired, a support layer is laminated thereon to obtain a laminate. Next, a cover having an adhesive layer disposed on one side is prepared. Next, one side of the cover on the adhesive layer side and one side of the laminate on the support layer side are bonded together to obtain a transdermally absorbable preparation. At this time, the sizes of the pressure-sensitive adhesive layer and the cover are adjusted in advance so that the pressure-sensitive adhesive layer covers the peripheral edge or end of one side of the drug-permeable membrane on the skin side.
- Examples of the solvent used in preparing the drug-containing layer and the adhesive layer in the above production method include ethyl acetate, butyl acetate, toluene, n-hexane, n-heptane, tetrahydrofuran, dimethylformamide, methanol or ethanol. Can be mentioned.
- the transdermally absorbable preparation according to the present invention can stably and efficiently administer an antidementia drug to a living body. Accordingly, the application period of the transdermally absorbable preparation is preferably 3 to 7 days, more preferably about 1 week.
- the drug administration plan may be appropriately determined by those skilled in the art according to the type of drug, patient symptoms, administration period, formulation size, and the like.
- an anti-dementia drug can be stably and efficiently administered transcutaneously even for a long period of about one week, and the patient whose symptoms have progressed Can also effectively treat dementia. Therefore, according to another aspect of the present invention, there is provided a method for treating dementia, comprising applying the transdermal absorption preparation to the skin of a living body once a week. When applied once a week, the transdermal absorption preparation of the present invention is preferably administered with an anti-dementia therapeutic drug at 21 mg to 70 mg / week.
- examples of the living body include rabbits, dogs, and humans, and humans are preferable.
- Example 1 Preparation of drug-containing layer Donepezil hydrochloride, Eudragit (registered trademark) E 100, triethyl citrate, glycerin, and SML (sorbitan monolaurate) were prepared in the proportions described above, and these were mixed and stirred in an appropriate amount of toluene. .
- SIS styrene-isoprene-styrene block copolymer, Kraton (registered trademark) D1111K, manufactured by Kraton) was added to the obtained mixed solution at a ratio of the following formulation to obtain a plaster solution.
- the plaster solution was applied onto a polyethylene terephthalate liner and dried at 70 ° C. for 15 minutes to obtain a drug-containing layer.
- the amount of the drug-containing layer after drying was adjusted to 100 g / m 2 .
- a support layer (Scotchpak TM 9732, manufactured by 3M) was laminated on one side of the drug-containing layer opposite to the liner. Thereafter, the liner was peeled from the drug-containing layer to obtain a laminate.
- Comparative Example 1 In accordance with the description in WO2007 / 129427, a reservoir-type transdermal absorption preparation having an adhesive layer, a microporous interlayer, and a drug-containing layer was prepared as follows.
- a drug-containing layer was prepared in the same manner as in Example 1 except that an acrylic polymer (Duro-Tak (registered trademark) 387-2516, manufactured by National Starch & Chemical) was used instead of SIS.
- an acrylic polymer (Duro-Tak (registered trademark) 387-2516, manufactured by National Starch & Chemical) was used instead of SIS.
- the liner of the drug-containing layer is peeled off, and it is laminated on one side opposite to the adhesive layer of the microporous polypropylene film, and a percutaneous absorption preparation similar to the structure described in WO2007 / 129427 is prepared. Obtained.
- Test example 1 In vitro human skin permeation test A flow-through cell in which the percutaneous absorption preparation (application area: 4.5 cm 2 ) of Example 1 or Comparative Example 1 was applied to the stratum corneum side of human skin and hot water was circulated so that the skin surface was about 32 ° C. 5 cm 2 ).
- As the receiver solution phosphate buffered saline (pH 7.4) was used, and the receiver solution was sampled every 4 hours up to 168 hours at a rate of 2.5 mL / hr. The amount of drug in the sampling solution was measured by HPLC. And the permeation
- the transition of the mean value of the donepezil plasma concentration + standard deviation was as shown in FIG.
- the maximum blood concentration C max (ng / mL) and AUC 0-168 (ng ⁇ hr / mL) for one week were as follows.
- C max (ng / mL) was 4.97 times and AUC was 3.29 times.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本明細書において、「アルキル」とは、直鎖状、分岐状または環状のアルキルを意味すし、好ましくは総炭素数が2~18である。
また、本明細書において、「アルコール」とは、直鎖状、分岐状または環状の飽和または不飽和アルコールを意味する。
本発明による経皮吸収製剤は、上述のように、特定の組成を有する薬物含有層を含んでなる。かかる薬物含有層を有する経皮吸収製剤が、顕著に高い貼付面積当たりの薬物放出量示すとともに、1週間程度の長期間にわたり、薬物を安定に放出しうることは意外な事実である。
さらに、上記塩基性薬物またはその塩は、好ましくは塩酸ドネペジル、塩酸メマンチン、酒石酸リバスチグミン、臭化水素酸ガランタミンまたは塩酸タクリンであり、より好ましくは塩酸ドネペジルである。
より具体例には、多価アルコール脂肪酸エステルとしては、モノラウリン酸ソルビタン、モノステアリン酸ソルビタン、モノオレイン酸ソルビタン、モノパルミチン酸ソルビタン、トリオレイン酸ソルビタンまたはトリステアリン酸ソルビタン等が挙げられるが、好ましくはモノラウリン酸ソルビタンである。
本発明における薬物含有層は、上記のような構成成分およびその量を用いる限り、適宜組み合わせて形成することができる。
そして、本発明の好ましい態様によれば、薬物含有層は、塩基性抗認知症薬物またはその塩;(メタ)アクリル酸ジアルキルアミノアルキルと、(メタ)アクリル酸アルキル、(メタ)アクリル酸ヒドロキシアルキルおよびこれらの組み合わせから選択されるモノマー単位とから構成される共重合体である、アミノ基を有する高分子化合物;多価アルコール脂肪酸エステル;多価アルコール;多価カルボン酸エステル;およびスチレン系高分子化合物を含んでなる。
また、上記好ましい組み合わせのいずれかにおいて、アミノ基を有する高分子化合物は、好ましくは(メタ)アクリル酸アクリル・(メタ)アクリル酸アルキル・(メタ)アクリル酸ジアルキルアミノエチルコポリマーであり、より好ましくはメタアクリル酸メチル・メタアクリル酸ブチル・メタアクリル酸ジメチルアミノエチルコポリマーである。
また、上記好ましい組み合わせのいずれかにおいて、多価アルコール脂肪酸エステルは、好ましくは糖アルコール脂肪酸エステルであり、より好ましくはソルビタン脂肪酸エステルである。
また、上記好ましい組み合わせのいずれかにおいて、多価アルコールは、好ましくは、グリセリンまたはグリコールであり、より好ましくはグリセリンである。
また、上記好ましい組み合わせのいずれかにおいて、多価カルボン酸エステルは、好ましくは2~6価カルボン酸エステルであり、より好ましくは2~3価カルボン酸C1~6アルキルエステルであり、さらに好ましくはセバシン酸エステルまたはクエン酸エステルである。
また、上記好ましい組み合わせのいずれかにおいて、スチレン系高分子化合物は、好ましくはスチレン-イソプレン-スチレンブロック共重合体、スチレン-ブチレン-スチレンブロック共重合体またはスチレン-ブタジエン-スチレンブロック共重合体であり、より好ましくはスチレン-イソプレン-スチレンブロック共重合である。
本発明による経皮吸収製剤の薬物含有層は、そのまま経皮吸収製剤として利用してもよいが、薬物含有層の固定手段を含んでなることが好ましい。
図1は、本発明による経皮吸収製剤の一実施形態を表す断面図である。
図1Aに示される通り、経皮吸収製剤は、皮膚側から順に、薬物含有層4、および支持体層3から構成される積層体と、積層体を皮膚上に固定しうる固定手段(1,2)とを備えている。
なお、薬物含有層は、そのまま皮膚に接触してもよいし、あるいは、薬物含有層の皮膚側の片面の一部には、薬物透過性を調節するための薬物透過性高分子膜を設置してもよく、本発明にはかかる態様も包含される。
また、粘着層の皮膚への接触面積は、薬物透過性膜の面積、投与期間等、貼付部位等を勘案して適宜決定することができる。
また、カバーは、例えば、支持体と同様の材料を用いることができる。
本発明による経皮吸収製剤の好ましい製造方法としては、以下の通りである。
まず、本発明による薬物含有層の構成成分を溶媒中で適宜混合し、溶媒中に構成成分を含む混合液を調整する。次に、この混合液を膏体溶液として用い、ライナー上に塗布する。次に、膏体溶液を60~120℃程度で乾燥させて薬物含有層を得、所望により、その上に支持体層をラミネートし、積層体を得る。次に、片面に粘着層が配置されたカバーを用意する。次に、カバーの粘着層側の片面と、積層体の支持体層側の片面とを張り合わせ、経皮吸収製剤を得る。なお、この際、粘着層が薬物透過性膜の皮膚側の片面の周縁部または端部を被覆するように、粘着層およびカバーのサイズを予め調整する。
本発明による経皮吸収製剤は、抗認知症薬物を安定かつ効率的に生体に投与しうる。よって、経皮吸収製剤の貼付期間は、好ましくは3~7日間、より好ましくは1週間程度である。もっとも、薬物の投与計画は、薬物の種類、患者の症状、投与期間、製剤のサイズ等に応じ、当業者によって適宜決定してもよい。
本発明による経皮吸収製剤によれば、1週間程度の長期間であっても、抗認知症薬物を安定して効率的に経皮的に投与することができ、症状が進行した患者においても認知症を効果的に治療することが可能となる。したがって、本発明の別の態様によれば、上記経皮吸収製剤を、生体の皮膚に1週間に1回貼付することを含んでなる認知症の治療方法が提供される。また、1週間に1回貼付の場合、本発明の経皮吸収製剤は、好ましくは抗認知症治療薬物を21 mg~70 mg/週で投与する。
薬物含有層の調製
塩酸ドネペジル、オイドラギット(登録商標)E 100、クエン酸トリエチル、グリセリン、およびSML(ソルビタンモノラウレート)を上記処方の割合で用意し、これらを適量のトルエン中で混合、撹拌した。得られた混合液に、SIS(スチレン-イソプレン-スチレンブロック共重合体、Kraton (登録商標)D1111K、Kraton社製)を下記の処方の割合で加え、膏体溶液を得た。
次に、薬物含有層のライナーと反対側の片面に支持体層(Scotchpak(商標)9732、3M製)をラミネートした。その後、薬物含有層からライナーを剥離し、積層体を得た。
Duro-Tak(商標) 87-2287(National Starch & Chemical製)をポリエチレンテレフタレート製ライナー上に塗工し、80℃15分間乾燥させ、粘着層を得た。乾燥後の粘着層の質量は、100g/m2とした。次に、ライナーと反対側の粘着層の片面にカバー層(ポリエステル製織布)をラミネートし、固定手段を得た。
次に、固定手段の粘着層上のライナーを剥離し、予め裁断しておいた積層体の支持体層と、固定手段の粘着層とを貼り合わせた。次に、粘着層および薬物含有層により形成される面に、ポリエチレンテレフタレート製ライナーを貼り合わせ、皮膚接触面を整え、裁断を行い、図1と同様の構成の経皮吸収製剤を得た。
WO2007/129427号公報に記載に準じて、以下の通り、粘着層、微孔性中間膜、および薬物含有層を有するリザーバー型経皮吸収製剤を調製した。
SISに代えて、アクリル系高分子化合物(Duro-Tak(登録商標) 387-2516、National Starch & Chemical社製)を用いる以外、実施例1と同様にして、薬物含有層を調製した。
クエン酸トリエチル 12g、ソルビタンモノラウレート 6gおよびアクリル系高分子化合物(Duro-Tak(登録商標)387-2516、National Starch & Chemical社製)239.9g(固形分42.5%)を混合撹拌した。得られた膏体溶液を、その厚さが乾燥後50μmとなるようにポリエチレンテレフタレート製ライナー上に塗布した。次に、ライナー上の膏体溶液を70℃10分間乾燥させて、所望の厚さの粘着層を形成した。この粘着層上に微孔性ポリプロピレン膜(Celgard(登録商標)2400、Celgard Inc.製)をラミネートした。 次に、上記薬物含有層のライナーを剥離し、それを微孔性ポリプロピレン膜の粘着層と反対側の片面にラミネートし、WO2007/129427号公報に記載される構成と同様の経皮吸収製剤を得た。
in vitro ヒト皮膚透過試験
ヒト皮膚の角質層側に実施例1または比較例1の経皮吸収製剤(適用面積4.5cm2)を貼付し、皮膚表面が約32℃となるように温水を循環させたフロースルーセル(5cm2)にセットした。レシーバー液としてはリン酸緩衝生理食塩液(pH 7.4)を使用し、レシーバー液のサンプリングは、2.5mL/hrの速さで4時間毎に168時間まで行った。サンプリング溶液は、HPLCにより薬物量を測定した。そして、4時間あたりの透過速度を算出し、単位面積あたりのフラックス(mcg/cm2/hr)の平均値を決定した。
また、皮膚透過量(mg/cm2)および最大フラックスJmax(mg/hr/cm2)については、以下の通りであった。
実施例1は、比較例1よりも、皮膚透過量および最大フラックスのいずれも高かった。
背部を剃毛したウサギ(オス、10週齢、n=6)に実施例1または比較例1の経皮吸収製剤35cm2を1枚貼付し、168時間後に剥離した。経皮吸収製剤を貼付後、2、4、8、12、24、48、72、96、120、144、168、170、172、174、および176時間の時点で採血を行った。得られたドネペジルの血漿中濃度をLC/MS/MSにより測定した。
また、最高血中濃度Cmax (ng/mL)および1週間のAUC0-168 (ng・hr/mL)は、以下の通りであった。実施例1は、比較例1と比較して、Cmax (ng/mL)は4.97倍であり、AUCは3.29倍であった。
Claims (16)
- 抗認知症治療薬物、アミノ基を有する高分子化合物、多価アルコール脂肪酸エステル、多価アルコール、多価カルボン酸エステル、およびスチレン系高分子化合物を含んでなる薬物含有層を含んでなる、抗認知症薬物の経皮吸収製剤。
- ヒトに対して1週間に1回貼付するための、請求項1に記載の経皮吸収製剤。
- 21mg~70mg/週の抗認知症治療薬物を経皮投与するための、請求項2に記載の経皮吸収製剤。
- 前記抗認知症薬物が塩基性薬物またはその塩である、請求項1~3のいずれか一項に記載の経皮吸収製剤。
- 前記抗認知症薬物が、塩酸ドネペジル、塩酸メマンチン、酒石酸リバスチグミン、臭化水素酸ガランタミンまたは塩酸タクリンである、請求項1~4のいずれか一項に記載の経皮吸収製剤。
- 前記アミノ基を有する高分子化合物が、(メタ)アクリル酸ジアルキルアミノアルキルと、(メタ)アクリル酸アルキル、(メタ)アクリル酸ヒドロキシアルキルおよびこれらの組み合わせから選択されるモノマー単位とから構成される共重合体である、請求項1~5のいずれか一項に記載の経皮吸収製剤。
- 前記アミノ基を有する高分子化合物が、(メタ)アクリル酸アクリル・(メタ)アクリル酸アルキル・(メタ)アクリル酸ジアルキルアミノエチルコポリマーである、請求項1~6のいずれか一項に記載の経皮吸収製剤。
- 前記多価カルボン酸エステルが2~6価カルボン酸エステルである、請求項1~7のいずれか一項に記載の経皮吸収製剤。
- 前記多価カルボン酸エステルが、セバシン酸エステルまたはクエン酸エステルである、請求項1~8のいずれか一項に記載の経皮吸収製剤。
- 前記多価アルコールが、糖アルコールまたはグリコールである、請求項1~9のいずれか一項に記載の経皮吸収製剤。
- 前記多価アルコールが、グリセリンまたはグリコールである、請求項1~10のいずれか一項に記載の経皮吸収製剤。
- 前記多価アルコール脂肪酸エステルが、糖アルコール脂肪酸エステルまたはグリコール脂肪酸エステルである、請求項1~11のいずれか一項に記載の経皮吸収製剤。
- 前記多価アルコール脂肪酸エステルが糖アルコール脂肪酸エステルである、請求項1~12のいずれか一項に記載の経皮吸収製剤。
- 前記スチレン系高分子化合物が、スチレンと、炭素原子2~8個の重合可能なアルケンとの共重合体である、請求項1~13のいずれか一項に記載の経皮吸収製剤。
- 前記スチレン系高分子化合物が、スチレン-イソプレン-スチレンブロック共重合体、スチレン-ブチレン-スチレンブロック共重合体またはスチレン-ブタジエン-スチレンブロック共重合体である、請求項1~14のいずれか一項に記載の経皮吸収製剤。
- 皮膚側から順に、前記薬物含有層および支持体層を含んでなる積層体と、
該積層体を皮膚上に固定しうる固定手段と
を含んでなる、請求項1~15のいずれか一項に記載の経皮吸収製剤。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10837661.7A EP2514415A4 (en) | 2009-12-16 | 2010-12-16 | TRANSDERMALLY ABSORBED PREPARATION OF ANTI-DEMENTIA MEDICINE |
JP2011546164A JP5800715B2 (ja) | 2009-12-16 | 2010-12-16 | 抗認知症薬物の経皮吸収製剤 |
KR1020127017558A KR20130000370A (ko) | 2009-12-16 | 2010-12-16 | 항인지증 약물의 경피흡수제제 |
CA2784712A CA2784712A1 (en) | 2009-12-16 | 2010-12-16 | Percutaneous absorption preparation comprising anti-dementia drug |
US13/516,580 US20120323190A1 (en) | 2009-12-16 | 2010-12-16 | Percutaneous Absorption Preparation Comprising Anti-Dementia Drug |
AU2010331243A AU2010331243A1 (en) | 2009-12-16 | 2010-12-16 | Transdermally absorbed preparation of anti-dementia drug |
CN201080063403.0A CN102834093B (zh) | 2009-12-16 | 2010-12-16 | 含有抗痴呆药物的经皮吸收制剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009285466A JP2012236773A (ja) | 2009-12-16 | 2009-12-16 | 抗認知症薬物の経皮吸収製剤 |
JP2009-285466 | 2009-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011074636A1 true WO2011074636A1 (ja) | 2011-06-23 |
Family
ID=44167387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/072667 WO2011074636A1 (ja) | 2009-12-16 | 2010-12-16 | 抗認知症薬物の経皮吸収製剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20120323190A1 (ja) |
EP (1) | EP2514415A4 (ja) |
JP (2) | JP2012236773A (ja) |
KR (1) | KR20130000370A (ja) |
CN (1) | CN102834093B (ja) |
AU (1) | AU2010331243A1 (ja) |
CA (1) | CA2784712A1 (ja) |
TW (1) | TW201127422A (ja) |
WO (1) | WO2011074636A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012043801A1 (ja) * | 2010-09-30 | 2012-04-05 | 積水メディカル株式会社 | 貼付剤 |
WO2015087927A1 (ja) | 2013-12-12 | 2015-06-18 | 久光製薬株式会社 | カバー材付き貼付剤及びカバー材付き貼付剤キット |
JP2019522024A (ja) * | 2016-07-27 | 2019-08-08 | コリウム インターナショナル, インコーポレイテッド | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
EP3656383A4 (en) * | 2017-07-19 | 2021-05-19 | Teikoku Seiyaku Co., Ltd. | RIVASTIGMIN-CONTAINING PERCUTICAL ABSORPTION PREPARATION |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014239687B2 (en) * | 2013-03-15 | 2018-04-05 | Nal Pharmaceutical Group Limited | Transdermal drug delivery system containing rivastigmine |
MY181540A (en) * | 2014-12-18 | 2020-12-28 | Icure Pharm Inc | Transdermal composition containing donepezil as active ingredient |
KR20180112768A (ko) * | 2015-12-10 | 2018-10-12 | 케이엠 트랜스덤 엘티디 | 경피 흡수 제제 |
CN109922796B (zh) | 2016-06-23 | 2023-04-07 | 考里安有限责任公司 | 具有亲水和疏水域的粘合剂基质和治疗剂 |
RU2764764C2 (ru) | 2016-07-27 | 2022-01-21 | Кориум Интернэшнл, Инк. | Трансдермальные системы доставки мемантина |
EP3490541A2 (en) | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs byin situ |
WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
CN117500923A (zh) | 2021-04-07 | 2024-02-02 | 巴特尔纪念研究院 | 用于鉴定和使用非病毒载体的快速设计、构建、测试和学习技术 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04117323A (ja) | 1990-09-04 | 1992-04-17 | Sekisui Chem Co Ltd | 経皮吸収貼付剤 |
JPH10182439A (ja) | 1996-12-20 | 1998-07-07 | Roehm Gmbh | 皮膚もしくは経皮の治療系のための付着−及び接合剤 |
JPH11315016A (ja) | 1998-03-03 | 1999-11-16 | Eisai Co Ltd | 抗痴呆薬を含有した経皮適用製剤又は坐剤 |
WO2002038139A1 (fr) | 2000-11-07 | 2002-05-16 | Hisamitsu Pharmaceutical Co., Inc. | Preparation pharmaceutique du type a absorption percutanee |
WO2003032960A1 (fr) | 2001-10-17 | 2003-04-24 | Hisamitsu Pharmaceutical Co., Inc. | Preparations pour absorption percutanee |
JP2004083523A (ja) * | 2002-08-28 | 2004-03-18 | Hisamitsu Pharmaceut Co Inc | 貼付剤 |
WO2007129427A1 (ja) | 2006-05-08 | 2007-11-15 | Teikoku Seiyaku Co., Ltd. | 抗認知症薬物の経皮吸収製剤 |
WO2007129712A1 (ja) * | 2006-05-09 | 2007-11-15 | Hisamitsu Pharmaceutical Co., Inc. | ドネペジル経皮吸収型製剤 |
WO2009145269A1 (ja) * | 2008-05-30 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 経皮吸収製剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6648893B2 (en) * | 2000-10-27 | 2003-11-18 | Blackstone Medical, Inc. | Facet fixation devices |
US20060260255A1 (en) * | 2003-09-11 | 2006-11-23 | Ganpule Ashok A | Multi-layered tile or block |
US20120283670A1 (en) * | 2009-12-16 | 2012-11-08 | Takeshi Ito | Percutaneous absorption preparation comprising anti-dementia drug |
US20120282303A1 (en) * | 2009-12-16 | 2012-11-08 | Takeshi Ito | Percutaneous absorption preparation comprising anti-dementia drug |
-
2009
- 2009-12-16 JP JP2009285466A patent/JP2012236773A/ja not_active Withdrawn
-
2010
- 2010-12-16 WO PCT/JP2010/072667 patent/WO2011074636A1/ja active Application Filing
- 2010-12-16 CA CA2784712A patent/CA2784712A1/en not_active Abandoned
- 2010-12-16 AU AU2010331243A patent/AU2010331243A1/en not_active Abandoned
- 2010-12-16 CN CN201080063403.0A patent/CN102834093B/zh not_active Expired - Fee Related
- 2010-12-16 TW TW099144232A patent/TW201127422A/zh unknown
- 2010-12-16 EP EP10837661.7A patent/EP2514415A4/en not_active Withdrawn
- 2010-12-16 US US13/516,580 patent/US20120323190A1/en not_active Abandoned
- 2010-12-16 JP JP2011546164A patent/JP5800715B2/ja active Active
- 2010-12-16 KR KR1020127017558A patent/KR20130000370A/ko not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04117323A (ja) | 1990-09-04 | 1992-04-17 | Sekisui Chem Co Ltd | 経皮吸収貼付剤 |
JPH10182439A (ja) | 1996-12-20 | 1998-07-07 | Roehm Gmbh | 皮膚もしくは経皮の治療系のための付着−及び接合剤 |
JPH11315016A (ja) | 1998-03-03 | 1999-11-16 | Eisai Co Ltd | 抗痴呆薬を含有した経皮適用製剤又は坐剤 |
WO2002038139A1 (fr) | 2000-11-07 | 2002-05-16 | Hisamitsu Pharmaceutical Co., Inc. | Preparation pharmaceutique du type a absorption percutanee |
WO2003032960A1 (fr) | 2001-10-17 | 2003-04-24 | Hisamitsu Pharmaceutical Co., Inc. | Preparations pour absorption percutanee |
JP2004083523A (ja) * | 2002-08-28 | 2004-03-18 | Hisamitsu Pharmaceut Co Inc | 貼付剤 |
WO2007129427A1 (ja) | 2006-05-08 | 2007-11-15 | Teikoku Seiyaku Co., Ltd. | 抗認知症薬物の経皮吸収製剤 |
WO2007129712A1 (ja) * | 2006-05-09 | 2007-11-15 | Hisamitsu Pharmaceutical Co., Inc. | ドネペジル経皮吸収型製剤 |
WO2009145269A1 (ja) * | 2008-05-30 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 経皮吸収製剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2514415A4 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012043801A1 (ja) * | 2010-09-30 | 2012-04-05 | 積水メディカル株式会社 | 貼付剤 |
WO2015087927A1 (ja) | 2013-12-12 | 2015-06-18 | 久光製薬株式会社 | カバー材付き貼付剤及びカバー材付き貼付剤キット |
KR20160096155A (ko) | 2013-12-12 | 2016-08-12 | 히사미쓰 세이야꾸 가부시키가이샤 | 커버재가 부착된 첩부제 및 커버재가 부착된 첩부제 키트 |
JPWO2015087927A1 (ja) * | 2013-12-12 | 2017-03-16 | 久光製薬株式会社 | カバー材付き貼付剤及びカバー材付き貼付剤キット |
JP2019522024A (ja) * | 2016-07-27 | 2019-08-08 | コリウム インターナショナル, インコーポレイテッド | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
EP3656383A4 (en) * | 2017-07-19 | 2021-05-19 | Teikoku Seiyaku Co., Ltd. | RIVASTIGMIN-CONTAINING PERCUTICAL ABSORPTION PREPARATION |
Also Published As
Publication number | Publication date |
---|---|
CA2784712A1 (en) | 2011-06-23 |
EP2514415A1 (en) | 2012-10-24 |
JP5800715B2 (ja) | 2015-10-28 |
EP2514415A4 (en) | 2014-03-26 |
TW201127422A (en) | 2011-08-16 |
US20120323190A1 (en) | 2012-12-20 |
JP2012236773A (ja) | 2012-12-06 |
JPWO2011074636A1 (ja) | 2013-04-25 |
KR20130000370A (ko) | 2013-01-02 |
CN102834093B (zh) | 2014-07-23 |
CN102834093A (zh) | 2012-12-19 |
AU2010331243A1 (en) | 2012-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5800715B2 (ja) | 抗認知症薬物の経皮吸収製剤 | |
JP5122445B2 (ja) | 抗認知症薬物の経皮吸収製剤 | |
JP5795264B2 (ja) | 抗認知症薬物の経皮吸収製剤 | |
US10987316B2 (en) | Compositions and methods for transdermal delivery of tertiary amine drugs | |
US8153151B2 (en) | Composition and method for controlling drug delivery from silicone adhesive blends | |
JP5615697B2 (ja) | β遮断剤の安定化組成物およびそれを用いた経皮吸収製剤 | |
EP2286814A1 (en) | Transdermal preparation containing palonosetron | |
WO2009026135A2 (en) | Controlled transdermal bisoprolol delivery system | |
WO2011074637A1 (ja) | 抗認知症薬物の経皮吸収製剤 | |
WO2005011683A1 (ja) | 経皮吸収型製剤 | |
WO2017006974A1 (ja) | 経皮吸収型貼付剤 | |
KR101964295B1 (ko) | 피부 자극이 감소된 메만틴 경피전달 시스템 | |
WO2009026133A2 (en) | Transdermal bisoprolol delivery system | |
MX2008014151A (es) | Preparaciones de absorcion percutanea de drogas contra demencia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080063403.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10837661 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2011546164 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2784712 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127017558 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6111/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010331243 Country of ref document: AU Ref document number: 2010837661 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010331243 Country of ref document: AU Date of ref document: 20101216 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13516580 Country of ref document: US |